Genetic Inactivation of Prokineticin Receptor-1 Leads to Heart and Kidney Disorders | Zendy

Mounia Boulberdaa | Zendy; Gülen Türkeri | Zendy; Kyoji Urayama | Zendy; Mojdeh Dormishian | Zendy; Cécilia Szatkowski | Zendy; Luc Zimmer | Zendy; Nadia Messaddeq | Zendy; Virginie Laugel | Zendy; Pascal Dollé | Zendy; Canan G. Nebigil | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genetic Inactivation of Prokineticin Receptor-1 Leads to Heart and Kidney Disorders

Author(s) -

Mounia Boulberdaa,

Gülen Türkeri,

Kyoji Urayama,

Mojdeh Dormishian,

Cécilia Szatkowski,

Luc Zimmer,

Nadia Messaddeq,

Virginie Laugel,

Pascal Dollé,

Canan G. Nebigil

Publication year - 2011

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.110.222323

Subject(s) - kidney , receptor , medicine , biology , endocrinology , cardiology

Prokineticins are potent angiogenic hormones that use 2 receptors, prokineticin receptor-1 (PKR1) and PKR2, with important therapeutic use in anticancer therapy. Observations of cardiac and renal toxicity in cancer patients treated with antiangiogenic compounds led us to explore how PKR1 signaling functioned in heart and kidney in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research